Nigeria lassa fever death rate rises despite fewer cases

Nigeria is confronting a troubling epidemiological puzzle as it enters March 2025: confirmed Lassa fever cases are declining, yet the virus's lethality appears to be intensifying. The Nigeria Centre for Disease Control (NCDC) reported 65 new infections in the final week of February, a decline from 77 cases the previous week, suggesting outbreak momentum may be slowing. However, this apparent progress masks a concerning trend—the case fatality rate is climbing despite fewer reported transmissions, raising critical questions about disease surveillance accuracy, healthcare system strain, and economic implications for European investors operating across Nigeria's healthcare, pharmaceutical, and financial sectors.

Lassa fever, a hemorrhagic viral illness endemic to West Africa, has periodically resurged across Nigeria, particularly in the northern and central regions where rodent reservoirs remain prevalent. The virus spreads through contact with infected animal droppings or direct human-to-human transmission in healthcare settings. Historically, Nigeria has experienced sporadic outbreaks; the 2018-2019 epidemic infected over 500 people with a 21% fatality rate. The current outbreak, which intensified in late 2024, has already prompted urgent public health mobilization, but the rising mortality-to-case ratio warrants deeper scrutiny.

The paradox of declining cases coupled with rising deaths suggests several operational realities on the ground. First, improved case detection and isolation protocols may mean that only the most severe cases are being confirmed and counted—milder infections go unrecorded, artificially skewing mortality statistics upward. Second, healthcare infrastructure strain in affected regions (primarily Ondo, Edo, and Bauchi states) could mean that confirmed patients, being sicker upon diagnosis, face worse outcomes. Third, delayed diagnoses and limited access to supportive care in rural areas may concentrate fatalities among hospitalized populations in urban centers.

For European investors, this outbreak carries immediate and indirect consequences. Medical device and pharmaceutical companies operating in Nigeria face both disruption and opportunity: diagnostic kit demand will surge, and companies positioned to supply RT-PCR testing equipment and supportive care medications stand to benefit. Conversely, supply chain disruptions, staff absenteeism in affected regions, and potential government-mandated movement restrictions could impact manufacturing operations and logistics networks. Insurance and reinsurance firms must reassess risk premiums for health-related coverage in Nigeria; elevated outbreak severity could trigger claim spikes.

The broader macroeconomic concern centers on Nigeria's healthcare system's resilience. Lassa fever outbreaks strain already-limited intensive care capacity and divert resources from routine healthcare delivery. For investors in Nigerian financial services, consumer goods, or manufacturing, workforce productivity losses mount as healthcare systems become overburdened. Additionally, international travel advisories—though unlikely to escalate to the level seen during Ebola—could dampen business travel and international conference attendance, slowing deal-making velocity.

The NCDC's epidemiological data will be critical to monitor in coming weeks. If case numbers continue declining while mortality stabilizes or decreases, it signals effective outbreak control. If mortality continues rising alongside case declines, it suggests surveillance gaps or healthcare system failure—both bearish signals for Nigeria's stability premium.